These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide. Morton MF; Barrett TD; Yan W; Freedman JM; Lagaud G; Prendergast CE; Moreno V; Pyati J; Figueroa K; Li L; Wu X; Rizzolio M; Breitenbucher JG; McClure K; Shankley NP J Pharmacol Exp Ther; 2007 Nov; 323(2):562-9. PubMed ID: 17684117 [TBL] [Abstract][Full Text] [Related]
4. Effect of three nonpeptide cholecystokinin antagonists on human isolated gallbladder. Maselli MA; Piepoli AL; Pezzolla F; Guerra V; Caruso ML; Mennuni L; Lorusso D; Makovec F Dig Dis Sci; 2001 Dec; 46(12):2773-8. PubMed ID: 11768273 [TBL] [Abstract][Full Text] [Related]
5. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Cremonini F; Camilleri M; McKinzie S; Carlson P; Camilleri CE; Burton D; Thomforde G; Urrutia R; Zinsmeister AR Am J Gastroenterol; 2005 Mar; 100(3):652-63. PubMed ID: 15743365 [TBL] [Abstract][Full Text] [Related]
6. [Applicability of CCK receptor antagonists in physiologic and therapeutic studies]. Heintges T; Niederau C Z Gastroenterol; 1992 May; 30(5):337-43. PubMed ID: 1632116 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic profile of dexloxiglumide. Persiani S; D'Amato M; Jakate A; Roy P; Wangsa J; Kapil R; Rovati LC Clin Pharmacokinet; 2006; 45(12):1177-88. PubMed ID: 17112294 [TBL] [Abstract][Full Text] [Related]
8. CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon. Fornai M; Colucci R; Antonioli L; Baschiera F; Ghisu N; Tuccori M; Gori G; Blandizzi C; Del Tacca M Eur J Pharmacol; 2007 Feb; 557(2-3):212-20. PubMed ID: 17208221 [TBL] [Abstract][Full Text] [Related]
9. Dexloxiglumide for the treatment of constipation predominant irritable bowel syndrome. Serra J; Caballero N Expert Opin Pharmacother; 2016 Oct; 17(14):1969-74. PubMed ID: 27590736 [TBL] [Abstract][Full Text] [Related]
10. Effect of selective CCK1 receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders. Lobo B; Serra J; D'Amato M; Rovati L; Malagelada JR; Santos J; Azpiroz F J Gastroenterol Hepatol; 2016 Feb; 31(2):288-93. PubMed ID: 26416485 [TBL] [Abstract][Full Text] [Related]
11. Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits. Sudo H; Yoshida S; Ozaki K; Muramatsu H; Onoma M; Yogo K; Kamei K; Cynshi O; Kuromaru O; Peeters TL; Takanashi H Eur J Pharmacol; 2008 Mar; 581(3):296-305. PubMed ID: 18164286 [TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of somatostatin on cholecystokinin octapeptide induced bile regurgitation under stress: ionic and molecular mechanisms. Si X; Huang L; Luo H; Shi R Regul Pept; 2009 Aug; 156(1-3):34-41. PubMed ID: 19445970 [TBL] [Abstract][Full Text] [Related]
19. Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats. Kanemitsu D; Sakagami J; Motoyoshi T; Nakajima T; Kataoka K Pancreas; 2006 Mar; 32(2):190-6. PubMed ID: 16552340 [TBL] [Abstract][Full Text] [Related]
20. Contribution of Rho-kinase in human gallbladder contractions. Büyükafşar K; Akça T; Nalan Tiftik R; Sahan-Firat S; Aydin S Eur J Pharmacol; 2006 Jul; 540(1-3):162-7. PubMed ID: 16730697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]